Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Cellectis SA ( (CLLS) ) is now available.
On May 12, 2026, Cellectis announced it will present new clinical data on its allogeneic CAR T candidates lasme-cel and eti-cel at the European Hematology Association congress in Stockholm from June 11-14, 2026. An oral presentation will cover full Phase 1 results from the BALLI-01 trial of lasme-cel in heavily pretreated relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia, underpinning a pivotal Phase 2 program now recruiting in Europe and North America.
The company will also share a poster from the Phase 1 NATHALI-01 study of eti-cel in relapsed or refractory B-cell non-Hodgkin lymphoma, highlighting early mechanistic insights into optimizing lymphodepletion for its dual CD20/CD22 allogeneic CAR T product. The EHA exposure and planned data disclosures in Q4 2026 for both programs reinforce Cellectis’ bid to strengthen its position in off-the-shelf CAR T, with potential implications for future registrational paths and competitive standing in hematologic oncology.
The most recent analyst rating on (CLLS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
The score is held back primarily by weak financial performance—persistent losses, renewed 2025 cash burn, and rising leverage—partly offset by a relatively constructive technical setup with the stock trading above several key moving averages. Valuation is constrained by negative earnings and the absence of a dividend.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a clinical-stage biotechnology company specializing in gene-edited cell and gene therapies, with a focus on allogeneic CAR T immunotherapies for oncology. Using an off-the-shelf, ready-to-use CAR T-cell platform and in-house manufacturing, it positions itself as an end-to-end gene editing player, with headquarters in Paris and sites in New York and Raleigh, NC. Cellectis’ shares trade on Nasdaq and Euronext Growth, targeting global investors in advanced therapeutics.
Average Trading Volume: 39,691
Technical Sentiment Signal: Buy
Current Market Cap: $272M
See more insights into CLLS stock on TipRanks’ Stock Analysis page.